Patient-centered outcomes with subcutaneous immunoglobulin use for infection control in primary and secondary immunodeficiencies: data of a GEIE Spanish Registry

Autores de IIS La Fe

• Sandra Martínez Mercader

  Autor

• Víctor García Bustos

  Autor

• Pedro Moral Moral

  Autor

• Carmen Martínez Buenaventura

  Autor

• Elisa Escudero Vergara

  Autor

• Carmen Montaner Bosch

  Autor

• Héctor Balastegui Martín

  Autor

• Marta Dafne Cabañero Navalón

  Autor

Participantes ajenos a IIS La Fe

• Maycas, SG
• Mur, BP
• Palazón, ME
• Mulet, MM
• Carrasco, IC
• López, A
• Ruiz, CDH
• Ruiz-López, L
• Guzmán, RG

Grupos

• Grupo de Investigación en Enfermedad de Alzheimer (GINEA)

• Infección Grave

• Investigacion clínica en enfermedades crónicas e Infección por el VIH

Abstract

Background and aim Subcutaneous immunoglobulin (SCIg) has emerged as an alternative to intravenous administration for patients with primary (PID) and secondary immunodeficiencies (SID), offering benefits such as fewer systemic adverse reactions and greater patient autonomy. However, comprehensive real-world data on SCIg use, including clinical and patient-centered outcomes, remain scarce. This study, conducted by expert immunodeficiency nursing teams, assesses the clinical characteristics, reported adverse effects, and quality-of-life outcomes associated with SCIg therapy with different formulations in patients with PID and SID across Spain.Methods A multicenter, cross-sectional study was conducted across 8 immunodeficiency nursing units in Spain, involving 223 adult patients treated with SCIg from 2004 to 2024. Data on demographics, comorbidities, SCIg treatment characteristics, reported adverse events, and quality-of-life metrics (EuroQol-5D-3L, Gij & oacute;n Scale) were collected and analyzed.Results The cohort (61.4% female, mean age: 47.1 years) included 65% PID patients, with common variable immunodeficiency being the most frequent diagnosis (39.8%). SCIg demonstrated good tolerability overall, with no significant differences in global adverse event rates between facilitated 10% (fSCIg) and 20% formulations. However, 10% fSCIg was associated with higher reported frequencies of mild local rash (58.7% vs. 36.9%, p=0.002) and fever (10.6% vs. 1.7%, p=0.01). Quality-of-life scores indicated minimal limitations in mobility and self-care, with a mean subjective health rating of 72.7/100. Patients using 20% SCIg required fewer educational sessions for self-administration compared to the 10% group.Conclusion The different SCIg formulations in this large, multicenter cohort was effective and generally well-tolerated, supporting its use for maintaining adequate IgG levels and promoting patient independence in PID and SID. The study's findings advocate for tailored approaches that optimize patient satisfaction and address individual needs, emphasizing the critical role of dedicated immunodeficiency nursing teams in ensuring safe, effective, and patient-centered SCIg administration.

Copyright © 2025 Martínez Mercader, Garcia-Bustos, Moral Moral, Martínez Buenaventura, Escudero Vergara, Montaner Bosch, Balastegui-Martín, Galindo Maycas, Palací Mur, Escobar Palazón, Moreno Mulet, Campanero Carrasco, López, Hernández Ruiz, Ruiz-López, Guzmán Guzmán and Cabañero-Navalon.

Keywords

• subcutaneous immunoglobulin (SCIg); primary immunodeficiency (PID); secondary immunodeficiency (SID); patient-centered outcomes; quality of life